Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Helicobacter pylori eradication significantly reduces the relapse rate of ulcer-like dyspepsia

Helicobacter pylori eradication results in a significant reduction in symptomatic relapse in patients presenting with ulcer-like dyspepsia in primary care, the BSG conference has been told.

News image

fiogf49gjkf04

A team from Oxford and Taplow, England, investigated the role of H. pylori eradication in the treatment of ulcer-like dyspepsia in primary care.

Their findings were reported to the British Society of Gastroenterology Annual Conference, held this week in Glasgow, Scotland.

543 patients from 64 primary care centers in the UK and Norway were enrolled into the study. Individuals with confirmed ulcer were excluded from the investigation.

364 patients were assessed as H. pylori-positive by near patient antibody blood test.

Of these, 181 patients were randomized to receive eradication therapy (lansoprazole 30 mg, clarithromycin 250 mg and amoxycillin 1g, all twice a day) for 1 week, followed by lansoprazole 30 mg once a day for 3 or 7 weeks, according to symptoms.

Ulcer-like dyspepsia relapse rate:
Eradication therapy group 37%
Lansoprazole only, H. pylori-positive 51%
Lansoprazole only, H. pylori-negative 59%
British Society of Gastroenterology Annual Meeting

183 subjects received placebo antibiotics and lansoprazole 30 mg once a day for 4 or 8 weeks.

179 H. pylori-negative patients received open treatment with lansoprazole 30 mg once a day for 4 or 8 weeks.

Epigastric pain, and other gastrointestinal symptoms, consultations, prescriptions, and investigations were recorded during the treatment period and over a 12-month follow-up phase.

The researchers found the relapse rate of ulcer-like dyspepsia during the follow-up period, to be 37% in subjects who underwent eradication therapy. In subjects receiving just lansoprazole, relapse rates were 51% and 59% for H. pylori-positive and negative individuals, respectively.

The average number of GI consultations and prescriptions was lower in the eradication group compared with the H. pylori-positive, non-eradicated group.

Richard Stevens, of the East Oxford Health Centre, concluded on behalf of the group, "H. pylori eradication resulted in a significant reduction in symptomatic relapse in patients presenting with ulcer-like dyspepsia in primary care.

"This was associated with a reduction in the number of GI consultations and prescriptions over the subsequent 12 months."

British Society of Gastroenterology Annual Meeting
20 March 2001

Go to top of page Email this page Email this page to a colleague

 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Autoimmune pancreatitis in children
 01 November 2017 
Heartburn relief in adolescents with GERD
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us